The House Quietly Voted to Extend Military Psychedelics Research to 2033
We missed this one when it happened back on July 22 — bubbling it up now because it's more consequential than the news cycle at the time gave it credit for. The House passed its version of the FY2027 defense authorization bill, 216-212, carrying two psychedelics amendments: one extends the Pentagon's psilocybin, MDMA, ibogaine, and 5-MeO-DMT research program for PTSD/TBI in active-duty service members from a 3-year window to 2033, the other codifies Trump's April 2025 psychedelics executive order into law and requires the VA to name an official within 90 days to coordinate psychedelic-therapy access across agencies. Ten co-sponsors, split roughly evenly R/D, led by Rep. Morgan Luttrell (R-TX). It still needs the Senate, which hadn't acted on it as of this writing — this is House passage, not final law.
Read at Marijuana Moment